Approved for use through 07/31/2003. OMB 0651-0032 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

2	Under the Paperwork Rec	luction Act of 1995, no per	sons are required to				on unless it u	ispiays a	Valid ONID CONTROL HOL	Ť
7	UTILITY				mey Docket No.	. P	PC19173A			
)	PATENT APPLICATION				Inventor	S	Steven Lee BENDER et al.			
	TRA	Title		l i	CRYSTAL STRUCTURE OF VEGFRKD: LIGAND COMPLEXES AND METHODS OF USE THEREOF					
	and a second sec	27C E P &1 53(h))	Express Mail Label No. EV341079785US							
(Only f	or new nonapplications under	Mall Stop Patent Applications ADDRESS TO: Commissioner for Patents								
See M	MPEP chapter 600 concern	Box 1450 Alexandria, VA 22313-1450								
1.	Fee Transmitta (Submit an original, a) Applicant claim See 37 CFR 1.	 CD-ROM or CD-R in duplicate, large table or computer Program (Appendix) Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) 								
4 . 5 .	Specification (preferred arrang) - Descriptive to - Cross Reference to or a compute to a compute	9. 10. 11. 12. 13. 14.	i. ii. ii. ii. iii. iii. iii. iii. iii	i. CD-ROM or CD-R (2 copies) ii. Paper						
6	1.63(c	17	or its	(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Other:						
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76. Continuation Divisional Continuation-in-part (CIP) Of prior application No: // Prior application information: Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts 19. CORRESPONDENCE ADDRESS										
Customer Number 28940 or Correspondence address below										
<u> </u>										
Nar										
1	iress		State	Т			Zip Code	Т		
City			State				Fax			
Col	untry (D. in the max)	Stephen D. Broden	Telephone	Por	gistration No. ((Attorney/		43,020	-	Г
	NAME (Print/type)	Stephen D. Prodnu	IK .		<u> </u>	Tuoiney//	igoni)		C0004	1

Signature

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for completed application form to the Chief Information Officer, U.S. Peatent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/17 (10-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OFCOMMERCE of information unless it displays a valid OMB control number

	Complete If Known											
FEE TRANSMITTAL						Application Number TBD						
for FY 2004						Filing Date				•	_	
	First Named Inventor				Stev	Steven Lee BENDER						
Effective 10/01/2003. Patent fees are subject to annual revision.						LABITUTE TAUTIO						
Applicant claims small status. See 37 CFR 1.27						Art Unit				04724		
Total Amount of Payment Attorney Docket No.						PC PC19173A FEE CALCULATION (continued)						
METHOD OF PAYMENT (check all that apply) Check Credit Card Money Other None						3. ADDITIONAL FEES						
☐ Check ☐ Credit Card ☐ Money ☐ Other ☐ None Order						Large Entity Small Entity						
☑ Deposit Account:						Fee (\$)	Fee Code	Fee (\$)	1	Fee Description		Fee Paid
Deposit Account						130	2051	65	Surcharge -	- late fee or oath		
Number Deposit Account	Agouror	ouron Pharmaceuticals, Inc.				50	2052	25	Surcharge-			
The Director is	he Director is authorized to: (check all that apply)						1053	130	Non-English			
Charge fee(s)	indicated be	elow	Credit any ov	erpayments	1812	2,520	1812	2,520	Forfiling a request for Ex Parte reexamination			
Charge any additional fee(s) or any underpayment of fee(s)						920*	1804	920* 1,840*	Requesting publication of SIR prior to Examiner action Requesting publication of SIR after			
Charge fee(s) to the above-iden	indicated be	elow, exe	cept for the filing fee		1805	1,840*	1005	1,040	Examiner a			
to the above-local			CULATION		1251	110	2251	55	Extension for reply within first month			
1, BASIC FIL		- 0/1	002/11011		1252	420	2252	210	Extension for reply within second month			
Large Entity						950	2253	475	_	or reply within third n		
Fee Fee	Fee	Fee	-		1254	1,480	2254	740	Extension f	or reply within fourth	month	
Code (\$) 1001 770	2001	(\$) 385	Fee Description Utility filing fee	Fee Paid 770	1255	2,010	2255	1,005	Extension 1	for reply within fifth m	onth	
1002 340	2002	170	Design filing fee		1401	330	2401	165 165	Notice of A	ppeal of in support of an ap	neal	
1003 530	2203	265	Plant filing fee		1402	330 290	2402	165 145	1	r oral hearing	ipçai	
1004 770 1005 160	2004	385 80	Reissue filing fee filing fee		1451	1,510	1451	1,510		institute a public use proce	eeding	
1005 160	1 2005		iming ico		1452	110	2452	55	Petition to	revive unavoidable		
Subtotal (1)s \$ 770						1,330	2453	665	Petition to	revive – unintentiona	ıl	
O EVYDA CL	VIM EEES				1501	1,330	2501	665	Utility issue fee (or reissue)			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE Extra Claims Fee from Fee Paid						480	2502	240	Design iss	ue fee		
	40	- 20** =	below = 20 x 18		1503	640	2503	320	Plant issue	efee		
Total Claims Independent	30	-3=	27 x 86	= 360	1460	130	1460	130	Petitions to	the Commissioner		<u> </u>
Claims	30	- 3 -	^		1807	50	4007	50	Dragossin	s foo under 37 CEP 1	1 17(a)	
Multiple Dependent = 2682						50 180	1807	180	Processing fee under 37 CFR 1.17(q) Submission of Information Disclosure Stmt			
	.				1806	160	1800	,60	Submissio	TO THOMESON DECISION		
Large Entity Fee Fee	Small E	Fee	Fee Description		8021	40	8021	40		each patent assignn		
Code (\$) 1202 18	2202	(\$) 9	Claims in excess of 2	0	1809	770	2809	385				
1201 86	2201	43	Independent claims in	excess of 3	1810	770	2810	385	(37 CFR 1.129(a)) For each additional invention to be examined (37 CFR 1.129(b))			
1203 290	2203	145	Multiple dependent cl	aim, if not paid	1801	770	2801	385	Request for Continued Examination (RCE)			
1204 86	2204	43	**Reissue independe	nt claims over original patent	1802	1802 900 1802 900 Request for expedited examination of a design application				ation		
1205 18 2205 9 **Reissue independent claims over original patent (\$) 3452						Other Fee (specify)						
		=		F-2 5 11	_	Subtatal (2)	/¢\	<u> </u>				
**or number	*Redu	ced by Bas	ic Filing			f applicable)	(\$)					
SUBMITTED BY Regis							0. 43	3,020	Complete l		858/622	-3087
Name (Printed/Type) Stephen D. Prodnuk						stration N mey Age		.,				
Signature		15	Tom									

Waming: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and /or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail No. EV341079785US in an envelope addressed to: Mail Stop: Patent Application, Commissioner for Patents, PO Box 1450, Alexandria, VA 22312-1450 on this D day of April 2004.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

In re the Application of:

Steven Lee Bender et al.

Serial No.: Not Yet Assigned

Filed: Herewith

For: CRYSTAL STRUCTURE OF VEGFRKD: LIGAND COMPLEXES AND METHODS OF

USE THEREOF

Mail Stop: Patent Application

Honorable Commissioner For Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- 1. Utility Patent Application Transmittal (one page)
- 2. Application Data Sheet (3 pages)
- 3. Fee Transmittal (one page in duplicate)
- 4. Specification (total 289 pages)
 - Claims (6 pages)
 - Abstract (one page)
 - Figures (3 pages)
- 5. Sequence Listing Statement (one page)
- 6. Sequence Listing (36 pages)
- 7. One Floppy Disk containing Sequence Listing
- 8. Postcard

Respectfully submitted,

Date: April 15, 2004

Stephen D. Prodnuk Attorney For Applicants Registration No. 43,020

Agouron Pharmaceuticals, Inc. A Pfizer Company Legal Division, Patent Department 10777 Science Center Drive San Diego, California 92121 Phone: (858) 622-3087

Fax: (858) 678-8233